Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Invested Capital (2023 - 2025)

CG Oncology filings provide 3 years of Invested Capital readings, the most recent being $752.6 million for Q4 2025.

  • On a quarterly basis, Invested Capital rose 2.62% to $752.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $752.6 million, a 2.62% increase, with the full-year FY2025 number at $752.6 million, up 2.62% from a year prior.
  • Invested Capital hit $752.6 million in Q4 2025 for CG Oncology, up from $687.6 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $752.6 million in Q4 2025 to a low of -$123.1 million in Q4 2023.
  • Median Invested Capital over the past 3 years was $560.6 million (2024), compared with a mean of $399.4 million.
  • Biggest five-year swings in Invested Capital: soared 760.66% in 2024 and later rose 2.62% in 2025.
  • CG Oncology's Invested Capital stood at -$123.1 million in 2023, then surged by 695.76% to $733.4 million in 2024, then increased by 2.62% to $752.6 million in 2025.
  • The last three reported values for Invested Capital were $752.6 million (Q4 2025), $687.6 million (Q3 2025), and $670.4 million (Q2 2025) per Business Quant data.